CJC-1295 Without DAC 5mg+IPA

For laboratory and in-vitro research use only. Not a drug. Not for human or veterinary use or consumption. This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.

The CJC-1295 (without DAC) and Ipamorelin blend pairs two synthetic research peptides studied for their combined effect on growth hormone pathways: CJC-1295 without DAC, a short-acting growth hormone releasing hormone (GHRH) analog, and Ipamorelin, a selective growth hormone secretagogue. Nexa Peptide Labs sells this blend strictly for laboratory and in-vitro research use; it is not an FDA-approved drug and is not evaluated for human use.

This particular pairing shows up constantly in growth hormone axis research because the two peptides act on separate receptors that both feed into GH release, a GHRH receptor and a ghrelin/GHS receptor, so studying them together lets researchers observe a more complete secretory response than either compound produces alone. This page covers what each compound is, what has actually been published about them, an important labeling distinction buyers often get wrong, and what to check before you buy from any supplier claiming to sell this blend.

What Is the CJC-1295 and Ipamorelin Blend?

This product combines two peptides with different mechanisms. CJC-1295 without DAC, also called Modified GRF (1-29), is a stabilized analog of the first 29 amino acids of human growth hormone releasing hormone, engineered for resistance to enzymatic breakdown compared to native GHRH. Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue through the ghrelin receptor pathway, releasing GH while showing minimal effect on cortisol, ACTH, or prolactin in the animal studies where this has been examined. Combining a GHRH receptor agonist with a ghrelin receptor agonist is a common research design because the two receptor pathways are believed to work synergistically on pituitary GH output.

An Important Distinction: CJC-1295 With DAC Versus Without DAC

Research listings for CJC-1295 are not all describing the same molecule, and this distinction matters for anyone reading the published literature. CJC-1295 exists in two forms. The DAC form includes a drug affinity complex, a chemical modification that binds reversibly to albumin in the bloodstream and extends the peptide’s duration of action to a period of several days. The form sold in this product, CJC-1295 without DAC, lacks that albumin-binding modification and behaves as a shorter-acting GHRH(1-29) analog, closer in duration to native growth hormone releasing hormone. Most of the published human pharmacology data on CJC-1295, including the study cited below, was conducted using the long-acting DAC form, not the without-DAC form sold here. Researchers comparing this product against the literature should account for that difference rather than assuming the two forms share the same pharmacokinetic profile.

What Published Research Says About CJC-1295

A 2006 study in the Journal of Clinical Endocrinology and Metabolism tested the long-acting DAC form of CJC-1295 in healthy adults at single and repeated doses of 30 or 60 micrograms per kilogram. The study reported sustained, dose-dependent increases in GH and IGF-I levels, with GH elevated two- to tenfold for six days or more after a single dose, IGF-I elevated one and a half- to threefold for nine to eleven days, and an estimated half-life of 5.8 to 8.1 days. As noted above, that long duration of action is a property of the DAC-conjugated form specifically and should not be read as a description of the without-DAC product sold on this page, which is cleared from circulation far more quickly.

What Published Research Says About Ipamorelin

The original pharmacology study describing Ipamorelin, published in European Journal of Endocrinology in 1998, tested the peptide in rats and conscious swine. The study reported that Ipamorelin released growth hormone with a potency comparable to or exceeding GHRP-6, while other growth hormone releasing peptides tested in the same models, GHRP-6 and GHRP-2, also raised ACTH and cortisol levels. Ipamorelin did not raise ACTH or cortisol beyond what was seen with GHRH stimulation alone, which the authors identified as evidence of selective GH secretagogue activity. The study noted human trials had not yet been conducted at the time of publication.

CJC-1295 and Ipamorelin Blend Specifications and Comparison

The table below compares the CJC-1295 and Ipamorelin blend against two related growth hormone axis research peptides in the same catalog category, for researchers selecting the right tool for a given protocol.

Related products: Ipamorelin (standalone) product page and Sermorelin product page.

Purity, Certificate of Analysis, and Batch Testing

Every batch of this blend is verified to 98% or higher purity using HPLC, with mass spectrometry used to confirm molecular identity for both peptides in the mix. A Certificate of Analysis specific to the production batch is available on request. Researchers purchasing for a funded study or institutional protocol should request the COA before ordering, not after. See the Certificate of Analysis and lab testing page for sample reports and testing methodology.

Sourcing the CJC-1295 and Ipamorelin Blend: What to Verify Before You Buy

This blend carries a regulatory detail that a research buyer should know about independent of anything specific to Nexa Peptide Labs: ipamorelin acetate was added to the FDA’s Category 2 list of bulk drug substances on September 29, 2023, meaning FDA has determined it presents significant safety risk for use in compounded drug products and cannot lawfully be compounded under the 503A or 503B pathways. That designation concerns the licensed pharmacy compounding pathway used to produce drug products for patients, a different regulatory lane than a laboratory research peptide sold under research use only labeling; it is not a finding about products like this one. It is still worth knowing, because it means any listing offering this blend with therapeutic claims, dosing instructions, or reconstitution guidance for injection is describing a use FDA has specifically flagged as high risk, and that gap between labeling and actual marketing is exactly the pattern FDA has cited in enforcement actions against other peptide sellers. CJC-1295 itself is not on the Category 2 list; a nomination covering it was withdrawn.

Before buying a CJC-1295 and Ipamorelin blend from any supplier, it is worth confirming three things. First, does the listing stick to research framing throughout, with no dosing charts, cycle lengths, or injection instructions that belong on a clinical product rather than a laboratory reagent. Second, does the Certificate of Analysis cover both peptides individually, not just a combined purity figure, and does it correspond to the specific batch being shipped. Third, is purity confirmed by HPLC and mass spectrometry rather than simply claimed on the label.

Storage and Handling for Research Use

Store the lyophilized peptide blend at minus 20 degrees Celsius or colder, protected from light and moisture, until it is used in a laboratory protocol. Repeated freeze thaw cycles reduce peptide integrity, so researchers typically aliquot on receipt rather than repeatedly accessing a single vial. As with any peptide reagent, handling should follow your institution’s standard laboratory safety procedures; this product is not labeled or supplied with directions for human administration.

Buying the CJC-1295 and Ipamorelin Blend From Nexa Peptide Labs

The CJC-1295 and Ipamorelin blend is for sale in single vials and bulk wholesale quantities to laboratories, contract research organizations, and academic institutions. Every order ships with batch documentation, and volume pricing is available for CROs and institutional buyers purchasing on a recurring basis. Researchers outside the United States, including Canada, Germany, and France, should confirm import and customs requirements for research peptides in their own country before ordering. See the research use policy page and the shipping and fulfillment FAQ for details.

Frequently Asked Questions

What is the CJC-1295 and Ipamorelin blend used for in research?

It is used in laboratory studies examining growth hormone axis signaling, including combined GHRH receptor and ghrelin receptor stimulation, pituitary secretory response, and GH pulse dynamics. It is a research reagent, not a treatment, and this page does not describe it as a therapy for any human condition.

Is the CJC-1295 and Ipamorelin blend approved for human or veterinary use?

No. Neither CJC-1295 nor Ipamorelin is an FDA-approved drug, and this product is not evaluated, labeled, or sold for human or animal use or consumption. It is sold exclusively for laboratory and in-vitro research applications by qualified buyers.

What is the difference between CJC-1295 with DAC and without DAC?

The DAC form includes a drug affinity complex that binds to albumin in the bloodstream and extends its duration of action to several days. The without-DAC form sold in this blend lacks that modification and clears the body much faster, behaving more like a short-acting GHRH(1-29) analog. Most published CJC-1295 human data describes the DAC form specifically, not the without-DAC form.

What does current published research show for CJC-1295?

A 2006 study in the Journal of Clinical Endocrinology and Metabolism found the long-acting DAC form of CJC-1295 produced sustained, dose-dependent increases in GH and IGF-I in healthy adults, with an estimated half-life of 5.8 to 8.1 days. That study concerns the DAC form, not the without-DAC form sold here.

What does current published research show for Ipamorelin?

The original 1998 pharmacology study in European Journal of Endocrinology found Ipamorelin released growth hormone in rats and swine with potency comparable to or exceeding GHRP-6, while showing minimal effect on ACTH or cortisol compared to other growth hormone releasing peptides tested in the same models, evidence the authors described as selective GH secretagogue activity.

Is Ipamorelin currently restricted by the FDA?

Ipamorelin acetate has been on FDA’s Category 2 list of bulk drug substances since September 29, 2023, meaning FDA has determined it presents significant safety risk for use in compounded drug products and it cannot lawfully be compounded under the 503A or 503B pathways. That designation applies to the licensed pharmacy compounding pathway, not to laboratory research peptides sold under research use only labeling, but buyers should be aware of it when evaluating any listing’s claims.

Is it legal to buy CJC-1295 and Ipamorelin for research purposes?

Research peptides sold with accurate research use only labeling, and marketed without human use or therapeutic claims, can generally be purchased by qualified buyers for laboratory use. Buyers should independently confirm current requirements in their own jurisdiction, particularly given Ipamorelin’s active Category 2 designation described above.

What does a Certificate of Analysis show for a two peptide blend?

For a combined product, a proper COA documents purity and identity testing for each peptide separately, by HPLC and mass spectrometry, along with the batch or lot number. A single combined purity figure without per compound detail is not sufficient to verify a blend.

How should the CJC-1295 and Ipamorelin blend be stored, and what is its shelf life?

Store the lyophilized peptide blend at minus 20 degrees Celsius or colder, away from light and moisture. Properly stored lyophilized peptide is generally stable for an extended period; researchers should aliquot on receipt to avoid repeated freeze thaw cycles, which shorten usable shelf life.

Do you ship the CJC-1295 and Ipamorelin blend to Canada, Germany, or France?

Nexa Peptide Labs fulfills United States orders directly and supports international peptide distributors; researchers outside the United States should confirm current import and customs requirements for research peptides in their own country before ordering.

What purity level should I expect when I buy a CJC-1295 and Ipamorelin blend online?

Reputable suppliers verify purity for each peptide in the blend by HPLC and provide a batch specific COA covering both compounds. Nexa Peptide Labs lists 98% or higher HPLC verified purity for each peptide in this blend; buyers comparing vendors should request the COA before purchase rather than relying on the listing alone.

Reviewed by , Nexa Peptide Labs Science and Quality Assurance Team.
Last updated: September 4, 2026.

Sources: Teichman, Neale, Lawrence, Gagnon, Castaigne, and Frohman, “Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults,” Journal of Clinical Endocrinology and Metabolism, 2006. Raun, Hansen, Johansen, Thogersen, Madsen, Ankersen, and Andersen, “Ipamorelin, the first selective growth hormone secretagogue,” European Journal of Endocrinology, 1998. FDA, Certain Bulk Drug Substances That Present Significant Safety Risks for Use in Compounding.